Business
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
- Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant - NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today
About this update from Nexttrip, Inc.
[{"type":"text","content":"- Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant -\n\n\nNEW YORK, Oct. 6, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease (\"AD\"). The study will be conducted in collaboration with the National Institutes of Health (\"NIH\") under a $2.7 million grant to Neurotrope. \nThe new Phase 2 clinical study, which is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda® (memantine) for a six-month period, which will include two 11-week dosing cycles. The study will focus on AD patients with pre-specified moderately severe (Moderate Stratum; MMSE-2 baseline score 14-10) and moderate (MMSE-2 baseline score 18–15) disease, including a patient population that demonstrated the most evidence of benefit in a prior study, and will focus on assessing sustained cognitive benefit as measured by the Severe Impairment Battery (\"SIB\") score, a widely accepted measure of cognitive function in advanced dementia patients. Analysis of the data will be conducted in consultation with Dr. Richard Thompson, Senior Scientist from the Bloomberg School of Public Health at Johns Hopkins University. \n\"After reviewing data from previous trials of Bryostatin-1 with both key opinion leaders and the NIH, we determined that a study to evaluate its long-term therapeutic effects in the absence of Namenda® in patients with AD was a priority,\" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. \"We have made rapid progress in commencing this study, and are very pleased to announce today that the first patient has been dosed after significant progress in patient enrollment. Among its potential effects, bryostatin has been shown, pre-clinically, to reverse damage to the synaptic connections between neurons that occurs in AD patients. AD remains among the most significant public health challenges of our modern era and, with support from the NIH, we hope to deliver progress toward advancing a new and innovative, disease modifying treatment.\"\nThis Phase 2 study is supported by Phase 2 clinical data from a completed pilot trial (NTRP101-202) which evaluated Bryostatin-1 in the absence of Namenda® in a short-term, 11-week treat...